BMI1-induced CD127+KLRG1+ memory T cells enhance the efficacy of liver cancer immunotherapy.

[1]  Marco Craveiro,et al.  Phenotypic plasticity and reduced tissue retention of exhausted tumor-infiltrating T cells following neoadjuvant immunotherapy in head and neck cancer. , 2023, Cancer cell.

[2]  V. Vezys,et al.  Functional T cells are capable of supernumerary cell division and longevity , 2023, Nature.

[3]  V. Master,et al.  CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. , 2022, Immunity.

[4]  Zhichen Sun,et al.  IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8+ T cells to overcome immunotherapy resistance in cancer , 2022, Nature Cell Biology.

[5]  S. Carty,et al.  OXPHOS promotes apoptotic resistance and cellular persistence in TH17 cells in the periphery and tumor microenvironment , 2022, Science Immunology.

[6]  Susan M. Schlenner,et al.  Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop. , 2022, Cancer cell.

[7]  Ping-Chih Ho,et al.  The mitochondrial pyruvate carrier regulates memory T cell differentiation and antitumor function , 2022, Cell metabolism.

[8]  S. Ansell,et al.  Expression of KLRG1 and CD127 defines distinct CD8+ subsets that differentially impact patient outcome in follicular lymphoma , 2021, Journal for ImmunoTherapy of Cancer.

[9]  Asha A. Nair,et al.  BMI1 maintains the Treg epigenomic landscape to prevent inflammatory bowel disease. , 2021, The Journal of clinical investigation.

[10]  B. Sangro,et al.  Advances in immunotherapy for hepatocellular carcinoma , 2021, Nature Reviews Gastroenterology & Hepatology.

[11]  Jianguo Wang,et al.  Targeting tumor-associated macrophages to synergize tumor immunotherapy , 2021, Signal Transduction and Targeted Therapy.

[12]  Huanming Yang,et al.  Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma , 2020, Cell.

[13]  Anteneh Getachew,et al.  Kupffer cells mediate the recruitment of hepatic stellate cells into the localized liver damage. , 2020, Biochemical and biophysical research communications.

[14]  Haiyang Xie,et al.  Hangzhou criteria as downstaging criteria in hepatocellular carcinoma before liver transplantation: A multicenter study from China. , 2020, Hepatobiliary & pancreatic diseases international : HBPD INT.

[15]  Howard Y. Chang,et al.  Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen , 2020, Nature Immunology.

[16]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[17]  L. Kennedy,et al.  A review of cancer immunotherapy toxicity , 2020, CA: a cancer journal for clinicians.

[18]  J. Ferlay,et al.  Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. , 2019, The Lancet. Global health.

[19]  Q. Gao,et al.  PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma , 2019, Journal of Immunotherapy for Cancer.

[20]  Ash A. Alizadeh,et al.  Determining cell-type abundance and expression from bulk tissues with digital cytometry , 2019, Nature Biotechnology.

[21]  M. Kalady,et al.  Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment. , 2019, Cell metabolism.

[22]  M. Fischbach,et al.  Bile acid metabolites control Th17 and Treg cell differentiation , 2018, bioRxiv.

[23]  A. Thomson,et al.  Hepatic Dendritic Cells, the Tolerogenic Liver Environment, and Liver Disease , 2018, Seminars in Liver Disease.

[24]  M. Kudo,et al.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.

[25]  B. Sangro,et al.  Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes , 2017, Clinical Cancer Research.

[26]  Ana C Anderson,et al.  Molecular Dissection of CD8+ T-Cell Dysfunction. , 2017, Trends in immunology.

[27]  Boxi Kang,et al.  Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing , 2017, Cell.

[28]  D. Miao,et al.  BMI‐1 Mediates Estrogen‐Deficiency–Induced Bone Loss by Inhibiting Reactive Oxygen Species Accumulation and T Cell Activation , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  Todd M. Allen,et al.  The epigenetic landscape of T cell exhaustion , 2016, Science.

[30]  Zhuxian Zhou,et al.  Esterase‐Activated Charge‐Reversal Polymer for Fibroblast‐Exempt Cancer Gene Therapy , 2016, Advanced materials.

[31]  F. Gao,et al.  Liver transplantation for hepatocellular carcinoma beyond the Milan criteria , 2015, Gut.

[32]  H. G. van der Poel,et al.  Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer. , 2012, The Journal of clinical investigation.

[33]  Huiyuan Li,et al.  Bmi-1 Regulates Autoreactive CD4+ T Cell Survival in Immune Thrombocytopenia Patients , 2012, Journal of Clinical Immunology.

[34]  James D. Johnson,et al.  MISC-1/OGC Links Mitochondrial Metabolism, Apoptosis and Insulin Secretion , 2011, PloS one.

[35]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[36]  A. Iwama,et al.  Bmi1 regulates memory CD4 T cell survival via repression of the Noxa gene , 2008, The Journal of experimental medicine.

[37]  H. Kawamoto,et al.  Thymocyte proliferation induced by pre-T cell receptor signaling is maintained through polycomb gene product Bmi-1-mediated Cdkn2a repression. , 2008, Immunity.

[38]  D. Fearon,et al.  Loss of T cell receptor-induced Bmi-1 in the KLRG1+ senescent CD8+ T lymphocyte , 2007, Proceedings of the National Academy of Sciences.

[39]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.